// App-Quantinova.ai

119 : Transcriptome profiles of NK and T cells regulating immune control in chronic hepatitis B, proximate to patients treated with Pegylated Interferon alpha‐Nucleos(t)ide analogue (NA) sequential therapy compared to de novo NA therapy.

Researchers

Presenter

  • Upkar S. Gill

Principal Investigators

  • Nina Le Bert

  • Kamini Kunasegaran

  • Atefeh Khakpoor

  • Navjyot K. Hansi

  • Damien Tan

  • Laura Rivino

  • Harsimran D. Singh

  • Wei-Chen Huang

  • Dimitra Peppa

  • Antonio Bertoletti

  • Mala K. Maini

  • Patrick T. Kennedy

Medical Centers

  • Hepatology, Centre for Immunobiology, Blizard Institute, Barts and The London, School of Medicine & Dentistry, QMUL, London, United Kingdom

  • Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore

  • Infection & Immunity Program, Singapore Institute for Clinical Sciences, Agency for Science, Technology & Research

  • Department of Infection and Immunity, University College London, London, United Kingdom

Locations

  • United Kingdom

  • Singapore

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Hepatitis B

Biomarkers

  • Alanine transaminase

  • Cluster of differentiation 8A

  • Interferon

  • Serum hepatitis B virus DNA

Drug/Treatment

  • Pegylated interferon alpha

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved